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Abstract
Background: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), gefitinib and erlotinib have been
tested as maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC). The studies are quite
heterogenous regarding study size and populations, and a synopsis of these data could give some more insight in the role
of maintenance therapy with TKI.
Methods: In September 2012 we performed a search in the pubmed, EMBASE and Cochrane library databases for
randomized phase III trials exploring the role of gefitinib or erlotinib in advanced non-small cell lung cancer. Through a
rigorous selection process with specific criteria, five trials (n = 2436 patients) were included for analysis. Standard statistical
methods for meta-analysis were applied.
Results: TKIs (gefitinib and erlotinib) significantly increased progression-free survival (PFS) [hazard ratio (HR) 0.63, 95%
confidence interval (CI) 0.50–0.76, I2 = 78.1%] and overall survival (HR 0.84, 95% CI 0.76–0.93, I2 = 0.0%) compared with
placebo or observation. The PFS benefit was consistent in all subgroups including stage, sex, ethnicity, performance status,
smoking status, histology, EGFR mutation status, and previous response to chemotherapy. Patients with clinical features
such as female, never smoker, adenocarcinoma, Asian ethnicity and EGFR mutation positive had more pronounced PFS
benefit. Overall survival benefit was observed in patients with clinical features such as female, non-smoker, smoker,
adenocarcinoma, and previous stable to induction chemotherapy. Severe adverse events were not frequent. Main
limitations of this analysis are that it is not based on individual patient data, and not all studies provided detailed subgroups
analysis.
Conclusions: The results show that maintenance therapy with erlotinib or gefitinib produces a significant PFS and OS
benefit for unselected patients with advanced NSCLC compared with placebo or observation. Given the less toxicity of TKIs
than chemotherapy and simple oral administration, this treatment strategy seems to be of important clinical value.
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Introduction
Current recommendations for chemotherapy treatment of
patients with advanced non-small cell lung cancer (NSCLC) are
four to six cycles as more cycles do not provide a survival benefit
but a higher risk of toxicity [1]. However, only 50–70% patients
will have second line treatment, while a substantial proportion of
patients do not get further therapy due to side effects or low
performance status [2,3]. Thus, exploration of a non-chemo
maintenance strategy has been a sensible development.
Maintenance therapy refers to the use of systemic therapy,
either by continuing the primary drug or switch to a new one, in
patients who get objective response or stable disease from the first
line chemotherapy. This was primarily tested with cytotoxic agents
such as gemcitabine [4], docetaxel [3] and pemetrexed [2]. The
outstanding results of the JMEN study proved that maintenance of
pemetrexed significantly improved the overall survival (OS) in
advanced NSCLC patients was a proof of principle [2].
Subsequently, the results of the SATURN study also showed a
significant prolongation of progression-free survival (PFS) and
overall survival (OS) with maintenance erlotinib compared with
placebo [5]. Zhang L et al [6] and other researchers [7,8] also
demonstrated the positive role of maintenance therapy with
epidermal growth factor receptor (EGFR) tyrosine kinase inhib-
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itors (TKIs), erlotinib and gefitinib. Due to their low toxicity and
good efficacy data, EGFR TKIs have aroused great attention in
maintenance therapy. Recently, the updated ASCO guidelines
recommended that immediate treatment with an alternative,
single-agent chemotherapy (including EGFR TKIs) in patients
may be considered [9].
Behera et al [10] carried out a meta-analysis focusing on the
role of single agent maintenance therapy in patients with advanced
non-small cell lung cancer. They included twelve studies (five
meeting abstracts, seven full manuscripts) and showed that single
agent maintenance therapy provided superior OS (HR 0.86, 95%
CI 0.80–0.92) and PFS (HR 0.62, 95% CI 0.57–0.67). However,
only four studies (two meeting abstracts and two full manuscripts)
about EGFR TKIs were included. Furthermore, because they
emphasized the role of switch and continuation, the outcomes of
EGFR TKIs maintenance were not analyzed in detail. Petrelli
et al [11] did a pooled analysis of three randomized trials of
erlotinib as maintenance therapy and confirmed the addition of
maintenance erlotinib significantly improved PFS and OS in
patients with advanced non-small cell lung cancer who had not
progressed after four cycles of first-line chemotherapy. The benefit
seemed to exist across the subgroups. But that analysis did not
include any study on gefitinib maintenance.
We thus conducted this meta-analysis of high quality random-
ized clinical trials on maintenance therapy with gefitinib and
erlotinib. Our aim was to determine the role of maintenance
EGFR TKIs in patients with advanced NSCLC and to explore
which subgroups of patients who will benefit from EGFR TKIs
maintenance.
Patients and Methods
Search Method
In September 2012, an electronic search of the Pubmed, the
EMBASE and the Cochrane library databases was performed.
The search keywords were: ‘‘gefitinib and maintenance’’, or
‘‘erlotinib and maintenance’’, ‘‘non-small cell lung cancer
(NSCLC)’’. The list of retrieved studies was then manually
searched and reviewed. The published languages and years were
not limited. Meeting abstracts from the American society of
Clinical Oncology (ASCO) (2007–2012) and World Congress of
Lung Cancer (WCLC) (2007–2011) were also hand searched for
eligible trials. Reference lists of original articles and review articles
were also examined for additional literature.
Selection of Trials
Details on the selection process are shown in the supplemen-
tary information file (Protocol S1). The selection of trials were
performed by two authors and blinded. Randomized controlled
phase III trials reporting the efficacy of gefitinib or erlotinib as
maintenance therapy (single or combined with other agents
except chemotherapeutics) immediately after the first line
chemotherapy in stage IIIB/IV NSCLC were considered
eligible. Patients should be pathologically or cytologically
diagnosed with NSCLC and randomized just before the
maintenance period. Peer-reviewed meeting abstracts fulfilling
the criteria were also included. All quality of all eligible studies
were also assessed by the Jadad Scale [12]. When a study had
updated data, both the original and updated papers or abstracts
were included. The references were screened by titles and
further selected by reading the abstracts. Papers fulfilling the
criteria were reviewed in detail. Articles were also obtained
from cross-checking references of publications.
Data Extraction
Two independent reviewers extracted all data from the
identified papers using standardized data compilation forms.
Disagreements were resolved by discussion. The methodological
quality of each paper was scrutinized and data such as the first
author, year of publication, number of patients, median age,
percentage of adenocarcinoma and data related to the clinical
outcomes such as objective response rate (ORR), progression free
survival (PFS), overall survival (OS), adverse events (AE) were
extracted. The final data were used when updated data were
available. Supplementary data of the IFCT-GFPC 0502 and
EORTC 08021/ILCP 01/03 study were obtained by contacting
the correspondent authors.
Statistics
The primary outcome of this systematic review is whether the
TKIs maintenance will produce OS benefit, the secondary
outcomes including PFS benefit, subgroups analysis regarding
OS and PFS, response rate and data on harms. First, the
outcome data were pooled and reported as hazard ratio (HR)
(fixed model or random model). HR ,1 represents results in
favor of TKI maintenance therapy. The PFS and OS were
estimated by collection of HRs with 95% Confidence Intervals
(CIs) which were mentioned in the original publications. The
pooled risk ratio (RR) for ORR was calculated from the
number of events and the number of patients at risk in each
group. Prespecified subgroup analysis according to clinical
features was also done.
The study heterogeneity was tested and a P,0.1 was defined as
heterogenous. A fixed-effect model (Mantel Haenszel) was applied
in case of absence of heterogeneity between studies and otherwise
a random-effect model was performed. The meta-analysis results
were displayed as forest plots. All calculations were performed
using Stata (version 11, Stata, USA).
Results
Study Selection Results
Our search in electronic database and meeting abstracts
retrieved 463 references. Of these, only five studies
[5,6,7,8,13,14] met the criteria. The selection steps are summa-
rized in the flow chart shown in Fig. 1. One phase III study
(WJTOG0203) [15] comparing 3 cycles of platinum-doublet
chemotherapy followed by gefitinib maintenance with continued
platinum-doublet chemotherapy in Japanese patients with ad-
vanced non-small cell lung cancer was excluded because the
randomization was performed before the beginning of chemo-
therapy rather than before the maintenance period and the
continuous use of chemotherapy. Another study, SWOG S0023
study [16], evaluated gefitinib maintenance in inoperable stage III
NSCLC patients who had not progressed after chemoradiotherapy
(concurrent cisplatin and etoposide with thoracic radiation, then 3
cycles docetaxel consolidation). This study was excluded because
the maintenance was not after first line chemotherapy and the
patients were not stage IIIB/IV.
The data of the final five studies containing a total of 2436
patients were in 7 publications. The results of the SATURN
study was formally published in Lancet Oncology in 2010 by
Cappuzzo [5], and the data in Asian patients were separately
reported in Lung Cancer most recently by Wu [17]. The
ATLAS study was initially reported at the 2009 ASCO annual
meeting by Miller [14], with updated OS in 2010 by
Kabbinavar [7]. The original and updated publications were
all included where the PFS and safety data were obtained from
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the original publications while the OS data were extracted from
the updated abstracts.
Characteristics of the Five Trials in the Review
All of the five trials identified were randomized and controlled
phase III trials, and all were of high quality assessed by the Jadad
scale (Score4 or more). Two of the studies [6,8] used gefitinib
(250 mg/qd) and the other three used erlotinib (150 mg/qd)
maintenance [5,7,13]. In all studies maintenance was commenced
after 4 cycles’ first line chemotherapy in stage IIIB/IV NSCLC.
All of the studies enrolled patients with a mixed population (EGFR
mutated and non-mutated) and two of the studies (INFORM and
SATURN) reported the outcomes of EGFR patients related to
EGFR status. Four studies were double blind and placebo
controlled, and only one trial (IFCT-GFPC 0502) [13] was open
label. This study investigated maintenance gemcitabine or
erlotinib versus observation, following induction chemotherapy.
Only the data of erlotinib and observation arms were extracted for
the present analysis. A total of 2436 patients were included where
the majority were of Caucasian, second largest group were Asian
(n = 521) and one study included patients of Arabic decent
(n = 54). There were 2391(98%) patients with ECOG performance
status 0–1, and 1512(62%) had adenocarcinoma. A summary of
the trial characteristics and clinical outcomes is provided in
Table 1.
Response Rate
Data on response rate was available only in three of the trials,
two with gefitinib and one with erlotinib and where the control
arms were placebo. The gefitinib studies INFORM and the
EORTC showed a higher response rate than the SATURN study
[5,6,8]. However, the overall response rate was 14.50% (n= 671)
in EGFR TKI maintenance and 3.8% (n= 682) in the control arm
respectively. The pooled RR was 3.80 (95% CI 2.49–5.79),
indicating that EGFR TKIs have a significant tumor shrinking
effect after induction with chemotherapy.
Progression Free Survival
TKI maintenance therapy provided significant improvement in
PFS (HR 0.63, 95% CI 0.50–0.76; I2 = 78.1%; Random model;
Fig. 2). The significance is consistent between gefitinib (HR 0.50,
95% CI 0.32–0.68) and erlotinib subgroups (HR 0.71, 95% CI
0.63–0.78). The INFORM study provided a much lower HR
(0.42, 95% CI 0.33–0.55) and this may lead to the heterogeneity
between the trials. When excluded the INFORM study, the results
turned out to be homogenous with a similar favorable HR (0.70,
95% CI 0.63–0.76; I2 = 0.0). We also did a cross-study subgroup
analysis by pooling the HRs of the common subgroups reported in
these studies. The results showed that the maintenance treatment
of EGFR-TKIs provided consistent PFS benefits in all subgroups,
including stage, sex, ethnicity, PS, smoking status, histology,
Figure 1. Flow-chart of the meta-analysis.
doi:10.1371/journal.pone.0059314.g001
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EGFR mutation status and previous response to chemotherapy
(Table 2). Notably, more impressive benefit was found in patients
with EGFR mutation (HR 0.12, 95% CI 0.03–0.21) according to
SATUN and INFORM study (Fig. 3).
Overall Survival
The heterogeneity between these trials regarding OS was not
significant (I2 = 0.0%, p= 0.95) and thus we used a fixed model to
pool the HRs. A significant improvement of OS was found in the
maintenance group (HR 0.84, 95% CI 0.76–0.93; Fig. 4). This was
also shown in the erlotinib subgroup (HR 0.85, 95% CI 0.75–0.94)
but not in gefitinib subgroup (HR 0.84, 95% CI 0.65–1.02). To
determine whether this result was heavily influenced by SATURN
study, the only trial that showed significant OS benefit in TKI
maintenance group., a pooled HR without SATURN study was
also calculated. A significant improvement of OS was still detected
in the maintenance group (HR 0.87, 95% CI 0.76–0.98), but not
in the erlotinib (HR 0.84, 95% CI 0.65–1.02) or gefitinib subgroup
(HR 0.89, 95% CI 0.75–1.03). Subgroups analysis according to
clinical features as female sex, adonocarcinoma, non-smoker,
smoker and stable disease to previous induction chemotherapy
conferred OS benefit by EGFR TKIs maintenance, while patients
who were male, non-adenocarcinoma, and responded to chemo-
therapy did not (Fig. 5–8). Subgroup analysis regarding ethnicity
and EGFR mutation status were available only in SATURN and
ATLAS study. We thus did not pool the HRs for these subgroups.
Data on Harms and Quality of Life
As the adverse events (AEs) were generally less frequent and
reported differently, we were unable to carry out a pooled analysis.
The most frequent AEs$grade 3 were rash and diarrhea, which
were more frequent in clinical trials on erlotinib. The incidence of
$grade 3 rash was 9% in the SATURN study, and 10.4% in the
ATLAS. The incidence of $ grade 3 diarrhea was 2% in the
SATURN study and 9.3% in the ATLAS. Assessment of quality of
life (QoL, by Functional Assessment of Cancer Therapy-Lung
instrument) was obtained from two studies (INFORM and
SATURN). In the INFORM study, a significantly higher
percentage of patients had a sustained clinically relevant
improvement in lung cancer symptoms with gefitinib than with
placebo. No significant difference in QoL was found for patients
receiving erlotinib compared with those receiving placebo in
SATURN study.
Discussion
The studies on maintenance therapy in advanced NSCLC are
heterogenous regarding to study design and compounds, but in
general the results are promising for this group of patients.
Importantly, the discussion on the trade-off between a gain in PFS
or OS versus the toxicity has called for less toxic substances
[18,19]. Recently the TKIs have shown activity in phase III
studies of unselected populations with advanced NSCLC with the
combined advantage of less toxicity and hospital admittance and
the ease of oral administration. Here we performed a meta-
analysis on all phase III studies on maintenance TKI treatment
where patients were included after the induction chemotherapy,
thus the data will more correctly refect the benefit or harm from
maintenance therapy. The results of our meta-analysis confirmed
that EGFR TKIs (gefitinib or erlotinib) maintenance therapy
could provide both PFS and OS benefit in patients with advanced
NSCLC who had not progressed after first line chemotherapy.
According to the pooled results, EGFR TKIs produced a
reduction of 37% and 16% in the risk of progression and death,
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respectively. Notably, though maintenance arms in all of the
studies showed significant benefit in PFS, a significant OS benefit
was only found in the SATURN study. Among the five included
studies, four were aimed to detect the PFS benefit in maintenance
groups and thus the study samples were probably not large enough
to detect the difference in OS. Also, the widespread use of second
and third line treatment at progression makes the value of OS as
end-point more obscure. The EORTC 08021/ILCP 01/03 [8]
study, which planed to enroll 598 randomized patients and
observe 514 deaths, was designed to test the OS difference, but
was prematurely closed due to low accrual after inclusion of 173
patients. This meta-analysis, by pooling the similar randomized
control studies, showed strong evidence of OS benefit in EGFR
TKI maintenance therapy, both in the erlotinib subgroup and in
total.
Clinical and biomarker guided therapy has convincingly been
demonstrated in the use of EGFR TKIs as both second line
[20,21,22] and first line [23] treatment. But this has not been fully
defined in maintenance therapy. We thus carried out a subgroup
analysis to explore the sub-populations who may benefit or benefit
more from maintenance therapy. Interestingly, the PFS benefit
existed in all the subgroups including stage, sex and ethnicity, PS,
smoking status, histology, EGFR mutation status and previous
response to chemotherapy. Patients with stage IIIB or IV, PS 0 or
1, objective response or stable to previous chemotherapy had
similar benefit with regard to PFS. Consistent with previous studies
in first line, patients who were Asian (HR 0.40, 95% CI 0.21–
0.58), female (HR 0.61, 95% CI 0.46–0.75), non-smoker (HR
0.53, 95% CI 0.31–0.75), those who had adenocarcinoma (HR
0.59, 95% CI 0.38–0.79) and most impressively, EGFR mutant
(HR 0.12, 95% CI 0.03–0.21) may benefit more from EGFR
TKIs. Moreover, a significant OS benefit was also found in
patients who were female (HR 0.73, 95% CI 0.58–0.89),
nonsmoker (HR 0.68, 95% CI 0.48–0.88), and smoker (HR
0.88, 95% CI 0.78–0.98) or had adenocarcinoma (HR 0.83, 95%
CI 0.71–0.95), according to subgroup analysis on OS. In the
EORTC study 54/173 patients were recruited in Cairo, Egypt,
and potentially this could affect the result if ethnic Egyptians had a
higher rate of EGFR mutated tumors. To our knowledge, there
are no available data on this. A large study on EGFR mutation
status in African-Americans showed no difference in frequency of
mutational status, but there is still very little known about other
ethnicities than Asian and Caucasian [24].
Although only 27% of patients in INFORM and 59% in
SATURN were available for the EGFR mutation analysis, the
impressive HR in EGFR mutant positive patients reinforce the
notion that EGFR mutation is a predictive biomarker for EGFR
TKIs. In the EORTC study, there were not enough cases tested
for EGFR to validate these findings. A series of studies
[23,25,26,27] have clearly proved the rationale of first line EGFR
TKIs in advanced NSCLC patients harboring EGFR active
mutation. Since EGFR TKIs can prolong the PFS and OS as
maintenance after first line chemotherapy in the same population,
then, which strategy will lead to better outcome? As the available
data in EGFR TKIs maintenance are still limited, especially the
data with EGFR mutation status, future studies should address this
question.
Nevertheless, the pooled analysis showed that patients with
EGFR wild type also benefit from TKI maintenance (this mainly
due to the effect of erlotinib in SATURN). As SATURN is the
only trial that showed significant PFS benefit (HR 0.77, 95% CI
0.61–0.97, p= 0.0243) in patients with EGFR wild type, the role of
EGFR TKIs in this population should be verified by more studies.
An ongoing study conducted by Roche (NCT01328951) may
contribute to this issue. This double-blind, placebo-controlled
study will evaluate the benefit of first-line maintenance erlotinib
versus erlotinib at the time of disease progression in patients with
advanced non-small cell lung cancer (NSCLC) who have not
progressed following four cycles of platinum based-chemotherapy.
Importantly, this study enrolls patients whose tumor does not
harbor an EGFR activating mutation.
Figure 2. Meta-analysis of hazard ratio (HR) for progression free survival (PFS).
doi:10.1371/journal.pone.0059314.g002
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Table 2. Summary of meta-analysis of progression free survival (PFS) in subgroups.
Subgroups Study ID HR (95% CI) Weight % Pooled HR (95% CI), I2,model
Stage IIIb SATURN 0.83(0.62–1.10) 39.57 0.61(0.34–0.88)
EORTC 08021/ILCP 01/03 0.47(0.20–1.13) 21.37 59.8%, Random
INFORM 0.46(0.28–0.77) 39.06
Stage IV SATURN 0.68(0.58–0.81) 36.9 0.57(0.38–0.76)
EORTC 08021/ILCP 01/03 0.63(0.45–0.89) 27.09 80.2%, Random
INFORM 0.41(0.30–0.55) 36.01
Male SATURN 0.78(0.66–0.92) 30.43 0.68(0.55–0.82)
EORTC 08021/ILCP 01/03 0.75(0.58–0.98) 22.07 60.1%, Random
IFCT-GFPC 0502 0.70(0.52–0.92) 22.07
INFORM 0.49(0.35–0.69) 25.43
Female SATURN 0.56(0.42–0.76) 28.09 0.52(0.37–0.68)
EORTC 08021/ILCP 01/03 0.63(0.48–0.83) 27.54 62.0%, Random
IFCT-GFPC 0502 0.64(0.38–1.08) 13.45
INFORM 0.34(0.22–0.51) 30.92
Asian SATURN 0.58(0.38–0.87) 27.45 0.40(0.21–0.58)
ATLAS 0.18(0.06–0.55) 27.45 62.0%, Random
INFORM 0.42(0.21–0.58) 45.10
Caucasian SATURN 0.75(0.64–0.88) 62.52 0.75(0.66–0.85)
ATLAS 0.76(0.61–0.92) 37.48 0.0%, Fixed
PS = 0 SATURN 0.59(0.45–0.77) 50.67 0.61(0.49–0.72)
ATLAS 0.65(0.47–0.91) 26.80 0.0%, Fixed
IFCT-GFPC 0502 0.60(0.39–0.87) 22.52
PS = 1 SATURN 0.77(0.65–0.92) 52.33 0.75(0.65–0.85)
ATLAS 0.72(0.57–0.91) 33.00 0.0%, Fixed
IFCT-GFPC 0502 0.75(0.65–0.85) 14.77
Non-smoker SATURN 0.56(0.38–0.81) 18.27 0.40(0.31–0.49)
EORTC 08021/ILCP 01/03 0.51(0.25–1.02) 5.70 0.0%,Fixed
ATLAS 0.34(0.19–0.61) 19.15
IFCT-GFPC 0502 0.30(0.11–0.81) 6.90
INFORM 0.36(0.25–0.51) 49.98
Smoker SATURN 0.74(0.58–0.93) 22.38 0.69(0.61–0.78)
EORTC 08021/ILCP 01/03 0.62(0.43–0.89) 12.96 10.9%, Fixed
ATLAS 0.76(0.62–0.93) 28.53
IFCT-GFPC 0502 0.74(0.58–0.96) 18.99
INFORM 0.52(0.35–0.75) 17.14
Adeno SATURN 0.60(0.48–0.75) 25.77 0.54(0.38–0.71)
ATLAS 0.64(0.52–0.80) 25.45 82.0%, Random
IFCT-GFPC 0502 0.63(0.46–0.86) 21.45
INFORM 0.33(0.24–0.46) 27.32
Non-adeno SATURN 0.76(0.60–0.95) 58.01 0.77(0.64–0.90)
ATLAS 0.86(0.44–1.27) 10.31 0.0%, Fixed
IFCT-GFPC 0502 0.79(0.72–1.08) 16.31
INFORM 0.72(0.46–1.14) 15.37
EGFR mut SATURN 0.10(0.04–0.25) 73.53 0.12(0.03–0.21)
INFORM 0.17(0.07–0.42) 26.47 0.0%, Fixed
EGFR SATURN 0.78(0.63–0.96) 90.69 0.79(0.63–0.94)
wild type INFORM 0.86(0.48–1.51) 9.31 0.0%, Fixed
Previous SATURN 0.68(0.56–0.83) 30.75 0.60(0.43–0.76)
SD EORTC 08021/ILCP 01/03 0.64(0.43–0.97) 18.89 67.8%, Random
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Another controversial issue is whether we can select suitable
patients for maintenance treatment according to the response to
first-line treatment. The results are conflicting. In SATURN trial,
patients who had stable disease after chemotherapy had a higher
OS from maintenance treatment (HR 0.72, 95% CI 0.59–0.89),
compared to those who responded to chemotherapy (HR 0.94,
0.74–1.20). Although no similar statistically significant difference
in the OS benefit was observed in other studies, this tendency was
also found in EORTC 08021/ILCP 01/03 and ATLAS study.
The pooled results of the three trials showed that patients who
experienced stable disease after first line treatment had a more
pronounced OS benefit (HR 0.76, 95% CI 0.64–0.88) than those
who gained objective response (HR 0.91, 95% CI 0.74–1.07).
However, both categories of patients can achieve similar PFS
benefit from EGFR TKIs maintenance (HR 0.66, 95% CI 0.49–
0.83 for SD patients and HR 0.65, 95% CI 0.48–0.82 for patients
who respond to chemotherapy).
A great advantage of EGFR TKIs is the less toxicity and easy
administration, which reinforce the feasibility of EGFR TKIs as
maintenance treatment. The summary of the adverse events
indicated the incidence of grade 3 or more AEs were generally
very low and most patients did not require dose reductions or
interruptions.
To strengthen the results of the present meta-analysis, the
inclusion criteria were strictly set. Phase II randomized studies
were excluded and the randomization had to be done only before
the beginning of maintenance so that the effect of the maintenance
therapy could be clearly evaluated. The included studies were
quite similar in design. Except in ATLAS study, the control groups
were placebo (four studies) or observation (IFCT-GFPC 0502).
Bevacizumab was previously recommended to use continuously
after combination with chemotherapy in advanced NSCLC
[28,29]. In the ATLAS study, bevacizumab was added to the
first line chemotherapy, and continued in both maintenance and
control groups. The only difference was the maintenance use of
Table 2. Cont.
Subgroups Study ID HR (95% CI) Weight % Pooled HR (95% CI), I2,model
IFCT-GFPC 0502 0.71(0.50–1.02) 19.62
INFORM 0.41(0.29–0.56) 30.75
Previous SATURN 0.74(0.60–0.92) 39.75 0.65(0.48–0.82)
ORR EORTC 08021/ILCP 01/03 0.55(0.33–0.91) 12.10 51.5%, Random
IFCT-GFPC 0502 0.67(0.47–0.94) 18.42
INFORM 0.44(0.29–0.66) 29.73
Abbreviations: HR, hazard ratio; 95% CI, 95% confidence interval; Adeno, adenocarcinoma; SD, stable disease; ORR, objective response rate.
doi:10.1371/journal.pone.0059314.t002
Figure 3. Meta-analysis of hazard ratio (HR) for progression free survival (PFS) according to EGFR mutation status. (A) EGFR mutation
positive. (B) EGFR wild type.
doi:10.1371/journal.pone.0059314.g003
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erlotinib. Thus, this study was regarded as eligible and was also
included in the erlotinib maintenance meta-analysis [10,11]. The
similarity in designs of included studies was important to confer
this meta-analysis greater reliability. However, there are some
limitations of the present meta-analysis that should be noted. First,
the analysis is not based on individual patient data which could
have provided further insight into the efficacy of the maintenance
strategy. Then, although the included studies are very similar in
Figure 4. Meta-analysis of hazard ratio (HR) for overall survival (OS).
doi:10.1371/journal.pone.0059314.g004
Figure 5. Meta-analysis of hazard ratio (HR) for overall survival (OS) according to sex. (A) Female. (B) Male.
doi:10.1371/journal.pone.0059314.g005
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Figure 6. Meta-analysis of hazard ratio (HR) for overall survival (OS) according to histology. (A) adenocarcinoma. (B) non-
adenocarcinoma.
doi:10.1371/journal.pone.0059314.g006
Figure 7. Meta-analysis of hazard ratio (HR) for overall survival (OS) according to previous response to induction chemotherapy.
(A) Objective response after induction. (B) Stable disease after induction.
doi:10.1371/journal.pone.0059314.g007
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structure, mechanisms of effect and clinical efficacy, differences on
safety profile and clinical effects are also observed between
gefitinib and erlotinib. Ideally, only studies published as full
manuscripts in peer-reviewed journals should be included, but due
to the lack of eligible studies, and after scrutiny of the quality, data
from the ATLAS study published in peer-reviewed meeting
abstracts was included. Not all studies provided detailed subgroups
analysis, and the sample sizes in subgroups were inevitably
underpowered. Finally, one should keep in mind that these trials
were all partly funded by pharmaceutical industry, with the
inherent conflict of interest and possible bias, but these studies
were all of high quality and were the only eligible studies to
examine the relevant question. The results of this meta-analysis
should therefore be carefully interpreted when used in clinical
practice.
Conclusion
In conclusion, we demonstrate that maintenance therapy with
EGFR TKIs (gefitinib and erlotinib) produces a significant PFS
and OS benefit for patients with advanced NSCLC compared
with placebo or observation. The PFS benefit is also significant in
all subgroups including stage, sex, ethnicity, PS, smoking status,
histology, EGFR mutation status and previous response to
chemotherapy. The toxicity associated with EGFR TKIs mainte-
nance was generally low and well tolerated. These data suggest
that maintenance with EGFR TKIs after first line chemotherapy is
a good treatment strategy in unselected patients with advanced
NSCLC, and an excellent option for patients with EGFR
mutation.
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